# Yusaku Nakabeppu
**Yusaku Nakabeppu** (中別府 雄作) is a Japanese molecular biologist known for work on the Fos/Jun transcription factors and on the cellular defense system against 8-oxoguanine, an oxidized DNA base.[1](https://researchmap.jp/read0171811/?lang=english)
| Key fact | Detail |
|---|---|
| Field | Molecular biology; oxidative DNA damage and repair, neurofunctional genomics[2](https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200901000430558291) |
| Signature work | "DNA binding activities of three murine Jun proteins: Stimulation by Fos", *Cell*, 1988[3](https://doi.org/10.1016/0092-8674(91)90504-r) |
| Training | DSc in molecular genetics, Kyushu University, March 1984, in Mutsuo Sekiguchi's laboratory[4](https://www.linkedin.com/in/yusaku-nakabeppu-322774237) |
| Institute leadership | Research Center for Nucleotide Pool (2011–2015); Medical Institute of Bioregulation (2016–2020)[1](https://researchmap.jp/read0171811/?lang=english) • [5](https://www.bioreg.kyushu-u.ac.jp/mib/about_directors_e.html) |
| Current role | Was Director, JSPS San Francisco Research Liaison Center[1](https://researchmap.jp/read0171811/?lang=english) • [12](https://www.jspsusa-sf.org/en/about/) |
## Education and early career
Nakabeppu studied veterinary science at the Faculty of Agriculture of the University of Miyazaki from 1975 to 1979, then, according to J-GLOBAL, moved to Kyushu University for a master's course in biology, specializing in molecular genetics, from 1979 to 1981.[2](https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200901000430558291) His graduate work was done in Mutsuo Sekiguchi's laboratory.[4](https://www.linkedin.com/in/yusaku-nakabeppu-322774237)
His affiliation on the papers from this period was the [Howard Hughes Medical Institute](https://www.edgepedia.org/howard-hughes-medical-institute) in Baltimore.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC402071/)
## Representative work
His 1988 paper in *Cell*, "DNA binding activities of three murine Jun proteins: Stimulation by Fos", showed that Fos stimulates the DNA binding of the Jun proteins, a result that helped define how the Fos and Jun oncoproteins cooperate as a transcription factor complex.[3](https://doi.org/10.1016/0092-8674(91)90504-r) A follow-up study in *The EMBO Journal* in 1989 concluded that in the Fos-Jun heterodimer the basic region of Fos contributes specific DNA-binding properties equivalent to those of Jun, and that Fos-Jun heterodimers and Jun alone, but not Fos alone, bind the AP-1 site (TGACTCA) and the cAMP response element.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC402071/)
In February 1991 he published in *Cell* the characterization of a naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity ([DOI](https://doi.org/10.1016/0092-8674(91)90504-r)).[3](https://doi.org/10.1016/0092-8674(91)90504-r) This protein, ΔFosB, is produced by selective splicing of the *fosB* gene and acts as a dominant inhibitor of Jun's transcriptional activation.[7](https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf) Later work in his CREST project showed that ΔFosB controls cell proliferation, differentiation, and cell death, and identified Galectin-1 isoforms as ΔFosB downstream factors that promote axonal regeneration without inducing cell death.[7](https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf)
## Research program at Kyushu University
Nakabeppu became professor in the Department of Biochemistry of the Medical Institute of Bioregulation in August 1997, and about a year later received support from the Japan Science and Technology Agency's CREST program for a project on oxidative damage to brain and neural cells, which he later credited with helping him establish the new laboratory.[1](https://researchmap.jp/read0171811/?lang=english) • [7](https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf) The project took up the then little-studied problem of DNA damage and repair in the brain, studying defense genes including MTH1, OGG1, MUTYH, APEX2, NEIL3, and ITPA alongside transcription-related genes.[7](https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf)
The central biochemical picture, laid out in his 2004 review in *Free Radical Research*, is a three-enzyme defense against 8-oxoguanine: MTH1 hydrolyses oxidized purine nucleoside triphosphates such as 8-oxo-dGTP, 8-oxo-dATP, and 2-hydroxy-dATP to monophosphates, preventing their incorporation into nuclear, and mitochondrial genomes; [OGG1](https://www.edgepedia.org/ogg1) excises 8-oxoG already present in DNA as a glycosylase; and MUTYH excises adenine mispaired opposite 8-oxoG, suppressing 8-oxoG-induced mutagenesis.[8](https://doi.org/10.1080/10715760410001688348) Mice lacking MTH1, OGG1, or MUTYH show increased susceptibility to spontaneous carcinogenesis of the liver, lung, or intestine.[8](https://doi.org/10.1080/10715760410001688348) CREST-era publications from the group reported increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in [Parkinson's disease](https://www.edgepedia.org/parkinsons-disease) (*Annals of Neurology*, 1999), the multi-forms of human MTH1 produced by alternative translation initiation and single nucleotide polymorphism (*Nucleic Acids Research*, 1999), and two major forms of human OGG1 encoded by alternatively spliced mRNAs.[7](https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf)
The program's most cited neurodegeneration result came in the *Journal of Clinical Investigation* in 2012: mice lacking MTH1 and/or OGG1 showed severe striatal neurodegeneration under oxidative stress, whereas mice lacking MUTYH, or OGG1 together with MUTYH, were resistant.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC3533558/) In other words, MTH1 and OGG1 protect neurons while MUTYH-mediated repair promotes degeneration, because 8-oxoG accumulation in neuronal mitochondrial DNA triggers calpain-dependent neuronal loss, and later accumulation in microglial nuclear DNA drives PARP-AIF-dependent microgliosis.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC3533558/) A 2021 study published in *Scientific Reports* extended this to Alzheimer's disease: MTH1 and OGG1 suppress 8-oxoguanine accumulation in the brain genome and prevent disease progression in model mice, and expression of both enzymes is markedly reduced in the brains of sporadic Alzheimer's patients.[1](https://researchmap.jp/read0171811/?lang=english) • [10](https://www.kyushu-u.ac.jp/ja/researches/view/581/) In an AppNL-G-F Alzheimer's model mouse, MUTYH deficiency attenuates microglial activation, and compounds that cause MUTYH degradation, such as glimepiride, have been suggested as candidate therapeutics.[1](https://researchmap.jp/read0171811/?lang=english)
## Career record, honors and roles
He directed the university's Research Center for Nucleotide Pool from April 2011 to March 2015, and the Medical Institute of Bioregulation from 1 April 2016 to 31 March 2020.[1](https://researchmap.jp/read0171811/?lang=english) • [5](https://www.bioreg.kyushu-u.ac.jp/mib/about_directors_e.html)
His funding record includes a JSPS Kiban (A) project from April 2017 to March 2020 and a Kiban (C) grant from April 2021 to March 2024 on mechanisms of oxidative brain dysfunction.[1](https://researchmap.jp/read0171811/?lang=english) His honors include the Japanese Cancer Association Encouragement Award in 2009 for work on control of cell proliferation by the proto-oncogenes *fos* and *jun*, and the 2009 Showa Shell Sekiyu Environmental Research Prize for analysis of DNA damage by reactive oxygen species and its repair mechanisms.[1](https://researchmap.jp/read0171811/?lang=english) • [2](https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200901000430558291) He has also served as a reviewer for Reactome's 2018 pathways on defective base excision repair associated with MUTYH.[11](https://reactome.org/content/detail/person/2395826)
## References
1. 中別府 雄作 (Yusaku Nakabeppu) – researchmap profile. https://researchmap.jp/read0171811/?lang=english
2. Nakabeppu Yusaku | Researcher Information | J-GLOBAL. https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200901000430558291
3. https://doi.org/10.1016/0092-8674(91)90504-r
4. Yusaku Nakabeppu – career record. https://www.linkedin.com/in/yusaku-nakabeppu-322774237
5. Directors | Medical Institute of Bioregulation, Kyushu University. https://www.bioreg.kyushu-u.ac.jp/mib/about_directors_e.html
6. The basic region of Fos mediates specific DNA binding (EMBO Journal, 1989). https://pmc.ncbi.nlm.nih.gov/articles/PMC402071/
7. JST CREST project report: 活性酸素による脳・神経細胞の障害とその防御機構. https://www.jst.go.jp/kisoken/crest/report/sh_heisei10/nou_mamoru/nakabeppu.pdf
8. The Defense Mechanisms in Mammalian Cells against Oxidative Damage in Nucleic Acids (Free Radical Research, 2004). https://doi.org/10.1080/10715760410001688348
9. 8-Oxoguanine causes neurodegeneration during MUTYH-mediated DNA base excision repair (J Clin Invest, 2012). https://pmc.ncbi.nlm.nih.gov/articles/PMC3533558/
10. 脳ゲノムへの8-オキソグアニンの蓄積を抑えるとアルツハイマー病の進展が防げる | 九州大学. https://www.kyushu-u.ac.jp/ja/researches/view/581/
11. Reactome | Nakabeppu, Y. https://reactome.org/content/detail/person/2395826
12. About Us | JSPS San Francisco Office. https://www.jspsusa-sf.org/en/about/
---
*Topic: Encyclopedia › Life and health › Life and health scientists › Life scientists › Researchers in molecular and cell biology › DNA replication, repair, and recombination*
*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026; Sep 30, 2026 · Edited: Sep 25, 2026; Oct 15, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license